Go Search
Products

Otsuka America Pharmaceutical, Inc. (OAPI), established in the U.S. in 1989, has since built a strong business foundation on commercializing Otsuka-developed and in-licensed products.

Therapeutic Categories

  • Neuroscience
  • Cardiovascular
  • Oncology
  • Medical Devices

Otsuka-Developed and In-Licensed Products 

ABILIFY®
(aripiprazole)
www.abilify.com

Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for ABILIFY.

SAMSCA®
(tolvaptan)
www.samsca.com

Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for SAMSCA.

IV BUSULFEX®
(busulfan)
www.busulfex.com

Please seeFULL PRESCRIBING INFORMATION including Boxed WARNING for
IV BUSULFEX.

Medical Device
Urea Breath® Test for H. Pylori
www.breathtek.com

Please see FULL PRESCRIBING INFORMATION for BreathTek.

SPRYCEL®
(dasatinib)
www.sprycel.com

Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for SPRYCEL.

PLETAL®
(cilostazol)

Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for PLETAL.

OAPI, OPDC and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989.
OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd.